News Search Results
Nov 24, 2025, 10:47 ET Made Scientific and Cellergy Therapeutics Announce Manufacturing Partnership to Advance First-in-Human Mitochondrial Therapy
U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Cellergy Therapeutics Ltd., a biotechnology company pioneering first-in-class mitochondrial transplantation therapies, today announced a manufacturing partnership to advance Cellergy's mitochondrial
More news about: Made Scientific, Inc.
Nov 24, 2025, 10:31 ET Biochips Market worth $21.36 billion by 2030 with 8.8% CAGR | MarketsandMarkets™
Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest market share due to its strong biotechnology and pharmaceutical industries, well-established research infrastructure, and high investment in precision medicine and genomics. The region is home
More news about: MarketsandMarkets
Nov 24, 2025, 10:01 ET Regenerative Medicine Market to Skyrocket to USD 403.86 Billion by 2032 Driven by Cell & Gene Therapy Breakthroughs, Stem Cell Advancements, and Multi-Indication Expansion
scientific advances, rapid commercialization of gene and cell therapies, rising prevalence of chronic diseases, and aggressive investment from biotechnology companies, regenerative medicine is positioned to become one of the fastest-growing healthcare markets of the decade.
More news about: DataM Intelligence 4 Market Research LLP
Nov 24, 2025, 09:56 ET NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has
More news about: NeuroSense
Nov 24, 2025, 09:00 ET ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems. Through this agreement, the companies will
More news about: ToolGen
Nov 24, 2025, 08:34 ET GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced a collaborative research agreement with Hokkaido University
More news about: GlycoNex, Inc.
Nov 24, 2025, 08:30 ET Amorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer Patients
worldwide.About AmorphicalAmorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims
More news about: Amorphical
Nov 24, 2025, 08:30 ET ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 24, 2025, 06:03 ET Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
2030, supported by rising clinical trial activity, cost-efficient production capabilities, and increasing government initiatives to strengthen biotechnology innovation. Countries such as China, Japan, and South Korea are accelerating approvals and expanding research ecosystems for cell-based therapies.Emerging
More news about: Mordor Intelligence Private Limited
Nov 24, 2025, 05:00 ET Global FSHD Innovation Hub Expands Board to Strengthen Leadership and Impact
leading research-focused patient organization for facioscapulohumeral muscular dystrophy (FSHD). The Hub serves as a global platform that connects biotechnology and pharmaceutical companies, researchers, and advocacy partners with data and resources to accelerate therapy development for FSHD. Learn more
More news about: Global FSHD Innovation Hub
Nov 24, 2025, 02:11 ET Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader
More news about: Pin Therapeutics
Nov 21, 2025, 17:32 ET Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100
More news about: GenScript Biotech Corporation
Nov 21, 2025, 16:39 ET Zymo Research Advances Wastewater Surveillance as Sponsor of the Microbes in Wastewater Symposium 2026
Biodesign Swette Center for Environmental Biotechnology at Arizona State University and Dr. Joan B. Rose, Nowlin Chair in Water Research and Director of the Water Alliance at Michigan State University, both internationally recognized pioneers in environmental biotechnology and water research."Having served
More news about: Zymo Research Corp.
Nov 21, 2025, 10:31 ET Patient-Derived Xenograft/PDX Model Market worth US$0.66 billion by 2030 with 12.5% CAGR | MarketsandMarkets™
of cancer and the need for predictive, patient-relevant preclinical systems are driving the adoption of these systems across the pharmaceutical, biotechnology, and academic sectors, enabling more precise drug discovery, biomarker validation, and translational oncology research.
More news about: MarketsandMarkets
Nov 21, 2025, 10:20 ET Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
drug revenues, bolstered by strong oncology pipelines and multi-indication expansion strategies.Emerging Players1. Vir Biotechnology, Inc. (USA)Has an investigational agent VIR-5500, a masked T-cell engager (TCE) targeting prostate-specific membrane
More news about: DataM Intelligence 4 Market Research LLP
Nov 21, 2025, 09:20 ET Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones
www.OSR-Holdings.com.About Vaximm AGVaximm AG is a privately held Swiss-German biotechnology company and a wholly owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell vaccination platform harnesses live,
More news about: OSR Holdings
Nov 21, 2025, 07:30 ET Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). The study, co-authored by Moligo and Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, further validates long, ssDNA as an optimal method
More news about: Moligo Technologies
Nov 20, 2025, 16:01 ET Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics
More news about: Innocan Pharma Corporation
Nov 20, 2025, 16:01 ET Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics
More news about: Innocan Pharma Corporation
Nov 20, 2025, 15:12 ET 2025 Double Helix Medals dinner raises over $7 million
Chris Evert and Martina Navratilova and biotechnology pioneer
More news about: Cold Spring Harbor Laboratory
Nov 20, 2025, 15:05 ET The Critical Need to Address Mental Health in the Rare Disease Community, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 20, 2025, 15:00 ET Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic
More news about: Graviton Bioscience
Nov 20, 2025, 14:58 ET Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Md., Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has engaged a construction firm to carry out
More news about: Northwest Biotherapeutics, Inc.
Nov 20, 2025, 14:55 ET How Evf2 lncRNA Advances Research in Brain and Neurodevelopmental Disorders, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 20, 2025, 14:40 ET Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Md., Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has engaged a construction firm to carry out
More news about: Northwest Biotherapeutics, Inc.